Randomised, multicentre, national, open-label trial evaluating the non-inferiority of antiretroviral dual therapy taken on 4 consecutive days per week versus antiretroviral dual therapy taken continuously, in HIV-1 infected patients with controlled viral load under antiretroviral dual therapy
